Ashwani Verma
Stock Analyst at UBS
(4.37)
# 1,273
Out of 5,058 analysts
209
Total ratings
56.7%
Success rate
10.5%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | Downgraded: Hold | $49 → $23 | $19.25 | +19.48% | 12 | Oct 14, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $115 → $104 | $63.43 | +63.96% | 14 | Oct 14, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $669 → $735 | $460.01 | +59.78% | 2 | Oct 14, 2026 | |
| UTHR United Therapeutics | Reiterated: Buy | $705 → $725 | $540.03 | +34.25% | 20 | Oct 13, 2026 | |
| INSM Insmed | Reiterated: Buy | $172 | $97.79 | +75.89% | 9 | Oct 7, 2026 | |
| VTRS Viatris | Reiterated: Buy | $23 → $26 | $17.44 | +49.08% | 8 | Oct 5, 2026 | |
| LEGN Legend Biotech | Rated: Hold | $28 → $24 | $19.04 | +26.05% | 11 | Oct 2, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $231 → $214 | $135.91 | +57.46% | 20 | Sep 28, 2026 | |
| JAZZ Jazz Pharmaceuticals | Rated: Buy | $315 → $337 | $209.65 | +60.74% | 18 | Sep 14, 2026 | |
| RPRX Royalty Pharma | Rated: Buy | $66 | $58.99 | +11.88% | 13 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 | $20.53 | +153.29% | 1 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $6 | $5.17 | +16.05% | 4 | Aug 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $13 | $7.82 | +66.24% | 3 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $25 | $18.90 | +32.28% | 4 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $113 | $111.57 | +1.28% | 13 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $40 → $52 | $60.99 | -14.74% | 9 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $10.93 | +0.64% | 6 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $116.23 | -38.05% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 → $48 | $39.08 | +22.82% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $162.22 | +59.66% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $220 | $283.48 | -22.39% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,080 | $1,208.74 | -10.65% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $43 | $37.51 | n/a | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 | $27.90 | n/a | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.05 → $1.1 | $1.05 | n/a | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $119 → $130 | $232.83 | n/a | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.21 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.6702 | n/a | 1 | Oct 11, 2022 |
Acadia Pharmaceuticals
Oct 14, 2026
Downgraded: Hold
Price Target: $49 → $23
Current: $19.25
Upside: +19.48%
Cytokinetics
Oct 14, 2026
Reiterated: Buy
Price Target: $115 → $104
Current: $63.43
Upside: +63.96%
Madrigal Pharmaceuticals
Oct 14, 2026
Reiterated: Buy
Price Target: $669 → $735
Current: $460.01
Upside: +59.78%
United Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $705 → $725
Current: $540.03
Upside: +34.25%
Insmed
Oct 7, 2026
Reiterated: Buy
Price Target: $172
Current: $97.79
Upside: +75.89%
Viatris
Oct 5, 2026
Reiterated: Buy
Price Target: $23 → $26
Current: $17.44
Upside: +49.08%
Legend Biotech
Oct 2, 2026
Rated: Hold
Price Target: $28 → $24
Current: $19.04
Upside: +26.05%
Neurocrine Biosciences
Sep 28, 2026
Reiterated: Buy
Price Target: $231 → $214
Current: $135.91
Upside: +57.46%
Jazz Pharmaceuticals
Sep 14, 2026
Rated: Buy
Price Target: $315 → $337
Current: $209.65
Upside: +60.74%
Royalty Pharma
Sep 8, 2026
Rated: Buy
Price Target: $66
Current: $58.99
Upside: +11.88%
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $52
Current: $20.53
Upside: +153.29%
Aug 24, 2026
Rated: Buy
Price Target: $6
Current: $5.17
Upside: +16.05%
Aug 11, 2026
Downgraded: Hold
Price Target: $52 → $13
Current: $7.82
Upside: +66.24%
Aug 3, 2026
Reiterated: Buy
Price Target: $23 → $25
Current: $18.90
Upside: +32.28%
Jul 28, 2026
Reiterated: Hold
Price Target: $113
Current: $111.57
Upside: +1.28%
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $60.99
Upside: -14.74%
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $10.93
Upside: +0.64%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $116.23
Upside: -38.05%
May 6, 2026
Reiterated: Buy
Price Target: $42 → $48
Current: $39.08
Upside: +22.82%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $162.22
Upside: +59.66%
Nov 7, 2025
Reiterated: Hold
Price Target: $220
Current: $283.48
Upside: -22.39%
Nov 7, 2025
Reiterated: Buy
Price Target: $1,080
Current: $1,208.74
Upside: -10.65%
Oct 14, 2025
Reiterated: Buy
Price Target: $50 → $43
Current: $37.51
Upside: n/a
Jul 29, 2025
Reiterated: Hold
Price Target: $18
Current: $27.90
Upside: n/a
Jul 21, 2025
Reiterated: Hold
Price Target: $1.05 → $1.1
Current: $1.05
Upside: n/a
Jul 14, 2025
Reiterated: Hold
Price Target: $119 → $130
Current: $232.83
Upside: n/a
Jun 17, 2025
Reiterated: Buy
Price Target: $5
Current: $2.21
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.6702
Upside: n/a